Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Bo Ni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-3795-4148; OpenAlex author ID A5100680752. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers

Papers 9

  1. The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2025.111098↗
  2. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. First author DOI 10.1038/s41422-025-01098-4↗
  3. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  4. Revealing splenectomy-driven microRNA hsa-7b-5p's role in pancreatic cancer progression. Co-author DOI 10.1016/j.isci.2024.109045↗
  5. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.02.046↗
  6. PLPP2 as a metabolic and immune marker for predicting survival and enhancing response to anti-PD1 therapy in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3952664/v1↗
  7. Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12264-023-01082-1↗
  8. Synchronous primary colorectal mucinous adenocarcinoma and pancreatic ductal adenocarcinoma: A case report. First author DOI 10.3892/ol.2023.13991↗
  9. Identification of DDX31 as a Potential Oncogene of Invasive Metastasis and Proliferation in PDAC. Co-author DOI 10.3389/fcell.2022.762372↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongjie Xie · 7 shared papers, 2022–2025 · strength 1.38
  2. Xiuchao Wang · 3 shared papers, 2023–2025 · strength 0.59
  3. Kaiyuan Wang · 3 shared papers, 2023–2025 · strength 0.59
  4. Liangliang Wu · 3 shared papers, 2022–2025 · strength 0.55
  5. Chongbiao Huang · 3 shared papers, 2024–2025 · strength 0.53
  6. Tiansuo Zhao · 3 shared papers, 2024–2025 · strength 0.53
  7. Tianxing Zhou · 3 shared papers, 2024–2025 · strength 0.53
  8. Guannan Sheng · 2 shared papers, 2024–2025 · strength 0.41
  9. Jihui Hao · 2 shared papers, 2024–2025 · strength 0.35
  10. Shengyu Yang · 2 shared papers, 2024–2025 · strength 0.34
  11. Weihao Zhang · 1 shared paper, 2025 · strength 0.25
  12. Weishuai Liu · 1 shared paper, 2025 · strength 0.25
  13. Xiaozhou Yu · 1 shared paper, 2025 · strength 0.25
  14. Tao Yang · 1 shared paper, 2024 · strength 0.23
  15. Junjin Wang · 1 shared paper, 2023 · strength 0.22
  16. Peng Jin · 1 shared paper, 2024 · strength 0.21
  17. Xiaona Wang · 1 shared paper, 2024 · strength 0.21
  18. Yuexiang Liang · 1 shared paper, 2024 · strength 0.21
  19. Bin Li · 1 shared paper, 2024 · strength 0.21
  20. Xudong Qiu · 1 shared paper, 2023 · strength 0.19
  21. Hui Cao · 1 shared paper, 2023 · strength 0.19
  22. Chunchao Zhu Zhu · 1 shared paper, 2023 · strength 0.19
  23. Xiang Xia · 1 shared paper, 2023 · strength 0.19
  24. Ying Ma · 1 shared paper, 2025 · strength 0.19
  25. Chao Yang · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.